“To Protect and to Serve” was the former motto of the Los Angeles Police Department.
“To Protect and Swerve” is the motto of tumor-associated immune cells like macrophages, neutrophils, and T-lymphocytes that have deviated or swerved from their sworn oath to defend the constitution (of the human body) against all enemies, foreign and domestic, and thrown their lot in with the treasonous cancer cells, which they serve and protect.
“To Protect and Unswerve” is the motto of the EpicentRx lead therapies, AdAPT-001 and RRx-001 (nibrozetone), that have been specifically designed to reprogram/hack immune cells and to bring them back into the fold, so that they serve, support and safeguard normal host cells, not cancerous ones. Hopefully, in this way, they turn nonresponsive ‘cold’ tumors into responsive ‘hot’ ones.
Ultimately, the success of these two therapies in cancers like sarcoma for AdAPT-001 and small cell lung cancer (SCLC) for RRx-001 (nibrozetone) will depend on the ‘swerves of the curves’, that is on how significantly they cause the Kaplan-Meier overall survival (OS) curves to separate from those of standard of care, as illustrated below.
If you’re interested to learn more about the mechanisms by which AdAPT-001 and RRx-001 (nibrozetone) cause immune cells to ‘unswerve’ themselves, you can read these blogs here and here.
Hopefully you’ll read them like we wrote them.
Unswervingly.